Clinical trials: Chemoradiotherapy
Lung Cancer, Esophageal Cancer
The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of…
- Trial name
- NCT06019455
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
ESCC
Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR）
This trial aims to assess efficacy and safety of immunotherapy combined with chemoradiotherapy for first-line treatment of esophageal squamous cell carcinoma.
- Trial name
- NCT06478355
- Testing
- Immunotherapy, Chemotherapy drug, radiotherapy
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Hebei Medical University Fourth Hospital
Newly Diagnosed Glioblastoma
A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
- Trial name
- NCT04600817
- Testing
- TJ107
- Where
- 16 sites in China, Hong Kong
- Volunteers
- 160 people
- Sponsor
- TJ Biopharma Co., Ltd.
Gastrointestinal Neoplasms
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase 3 placebo-controlled trial to determine efficacy of the probiotic LGG for reducing acute treatment related GI toxicity in patients with GI malignancy with phase 1 safety lead-in.
- Trial name
- LGG (NCT01790035)
- Testing
- LGG
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer
Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer
The purpose of this study is to determine the efficacy and toxicity of docetaxel/cisplatin/5-fluorouracil induction chemotherapy (4 cycles) followed by concomitant chemoradiation with cetuximab and weekly cisplatin in patients…
- Trial name
- NCT00868491
- Testing
- docetaxel, cisplatin, 5-fluorouracil, radiotherapy, cetuximab, cisplatin
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- Institute of Oncology Ljubljana
Sarcopenia
Omega-3 Supplementation in Cervix Cancer Patients Undergoing Chemoradiotherapy
Cancer cachexia is a complex metabolic process affecting up to 80% of patients suffering from an advanced-stage cancer. Moreover, 20 to 40% of all cancer deaths are caused directly by cachexia.
- Trial name
- NCT02779868
- Testing
- Omega-3, Olive oil
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Brazilian National Cancer Institute
Lung Cancer
SDC for Lung Cancer Patients Treated With Curative Primary or Postoperative Radiotherapy or Chemoradiation
Introducing standardized data collection (SDC) for lung cancer patients to improve the performance of the prediction models.
- Trial name
- SDC lung (NCT01855191)
- Where
- Netherlands
- Volunteers
- 864 people
- Sponsor
- Maastricht Radiation Oncology
Esophageal Squamous Cell Carcinoma
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
This study aims to evaluate the impact of the neoadjuvant treatment strategy based on CPS score on the pathological complete response (pCR) rate in patients with resectable locally advanced esophageal cancer.
- Trial name
- ESCC (NCT06601309)
- Testing
- Serplulimab, Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy), Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Medical University Union Hospital
Rectal Cancer
Local Excision of Clinical T3 Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy
The purpose of this study is evaluation of the safety and the efficacy of transanal local excision in patients with cT3 rectal cancer which was downstaged into ycT0-1 after neoadjuvant chemoradiotherapy.
- Trial name
- NCT02490709
- Testing
- Local excision
- Where
- South Korea
- Volunteers
- 86 people
- Sponsor
- National Cancer Center, Korea
Esophageal Cancer, Chemoradiation
Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal Cancer
The investigators designed a new preoperative chemoradiotherapy regimen to focus on the most important radiation area and hope to reduce the radiation volume and try to reduce the postoperative mortality and treatment-related…
- Conditions
- Esophageal Cancer, Chemoradiation, Surgery
- Trial name
- NCT02938195
- Testing
- radiotherapy, Surgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Nasopharyngeal Carcinoma
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
This is a phase 3, multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 blockade (toripalimab) combined with the de-intensified chemoradiotherapy sparing concurrent…
- Trial name
- DIAMOND (NCT04907370)
- Testing
- PD-1 blocking antibody, Gemcitabine, Cisplatin (80mg/m2)
- Where
- 12 sites in China
- Volunteers
- 532 people
- Sponsor
- Sun Yat-sen University
Pancreatic Cancer Stage II, Pancreatic Cancer Stage III
Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III)
This study is for patients with locally advanced pancreatic cancer (cancer that involves the local blood vessels so it cannot be removed without cutting major blood vessels) that cannot be treated with surgery.
- Trial name
- NCT01065870
- Testing
- Neoadjuvant gemcitabine, capecitabine, and docetaxel, Gemcitabine, capecitabine, docetaxel followed by radiotherapy
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Columbia University
Head and Neck Cancer, Radiation
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study
To investigate whether concurrent Tislelizumab with postoperative chemoradiotherapy would have survival benefit in high Risk HNSCC Patients.
- Conditions
- Head and Neck Cancer, Radiation, PD-1
- Trial name
- NCT04814069
- Testing
- Tislelizumab
- Volunteers
- 38 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Rectal Cancer Patients
Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer
Research Objective:To investigate the efficacy and safety of the "total neoadjuvant chemoradiotherapy combined with immunotherapy" regimen for the treatment of locally advanced rectal cancer with high-risk features for…
- Trial name
- TNT-Immunity (NCT07214142)
- Testing
- PD-1
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
Oropharyngeal Carcinoma, De-escalation
De-escalation Protocols in HPV-related Oropharyngeal Carcinoma in Chinese Populations
Human papillomavirus (HPV)-related oropharyngeal carcinoma are exquisitely radiosensitive. Several studies attempted to reduce the toxicities of treatments through reduced-dose radiation and showed promising results, but all data…
- Trial name
- NCT04012502
- Testing
- Toxicities reduced treatment, conventional treatment
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Fudan University
Colorectal Cancer
Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00023751
- Testing
- fluorouracil, leucovorin calcium, conventional surgery
- Where
- 180 sites in United States, Canada and 1 more
- Volunteers
- 320 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Early Low Rectal Cancer
Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer
TORCH-E2 is a prospective, multicentre, randomized phase II trial. 134 low-lying early (T1-3b/N0-1M0, distance from anal verge ≤5cm) patients will be recruited and assigned to Group 1 and Group 2 (1:1).
- Trial name
- TORCH-E2 (NCT06462053)
- Testing
- Short-course radiotherapy, PD-1 antibody (Toripalimab), Long-course radiotherapy
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Fudan University
Esophageal Cancer
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma (ESCC). Aim to evaluate the efficacy and safety of Iparomlimab consolidation therapy following concurrent…
- Trial name
- NCT07038629
- Testing
- S1, Iparomlimab, Radiation
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Head Neck Cancer, Swallowing Disorders
Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer
General Objective: To evaluate the swallowing results of speech pathologist rehabilitation of advanced oropharynges, larynx and hypopharynx cancer patients during neoadjuvant chemotherapy and radiotherapy concomitant to…
- Trial name
- Swallowing-1 (NCT02075385)
- Testing
- pre, during and pos-treatment swallowing exercises
- Where
- Brazil
- Volunteers
- 94 people
- Sponsor
- Barretos Cancer Hospital
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS)…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Trial name
- NCT04210115
- Testing
- pembrolizumab, cisplatin, 5-FU
- Where
- 170 sites in United States, Argentina and 25 more
- Volunteers
- 703 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.